Purpose To evaluate the risk of locoregional recurrence (LRR) associated with locoregional
treatment of women with primary breast cancer tumors negative for estrogen receptor, …

Resistance to trastuzumab, the monoclonal antibody targeting human epidermal growth
factor receptor 2 (HER-2), is a major concern for HER-2–positive metastatic breast cancer (MBC…

Angiogenesis inhibitors, such as sunitinib, represent a promising strategy to improve
glioblastoma (GBM) tumor response. In this study, we used the O 6 -methylguanine …

Resistance to trastuzumab, a rationally designed HER-2-targeting antibody, remains a major
hurdle in the management of HER-2-positive breast cancer. Preclinical studies suggest the …

Background Modern breast surgical oncology incorporates many aspects of care including
preoperative workup, surgical management, and multidisciplinary collaboration to achieve …

The majority of patients undergoing bilateral prophylactic mastectomy request immediate
implant-based breast reconstruction. Some patients, especially those with prior radiotherapy, …

Background Preserving the nipple-areolar complex (NAC) in breast cancer surgery improves
patient satisfaction and quality of life. The oncologic safety of NSM in tumors < 2 cm from …

Introduction Breast cancer in women with cosmetic breast implants is increasingly common.
Over the past decade, there has been a push for mastectomy and reconstruction in these …

Background: The ability to accurately predict which patients will achieve a pathologic complete
response (pCR) after neoadjuvant chemotherapy could help identify those who could …

5826 HER-2, a member of the epidermal growth factor receptor family is overexpressed in ~25-30%
of invasive breast cancers and correlates with a poor prognosis and aggressive …